Fontan术后血管加压素输注的安全性与疗效:随机初步研究
一项随机双盲安慰剂对照初步研究纳入20例Fontan术后患者,评估24小时血管加压素输注对血流动力学和液体平衡的影响。结果显示血管加压素组跨肺压差和术后48小时胸管引流量显著低于安慰剂组,两组在血钠、肝肾功能方面无差异,提示该干预安全且可能改善早期术后指标。
要点
- Fontan术后24小时血管加压素输注安全,未增加肝肾功能或血钠异常。
- 血管加压素组跨肺压差显著低于安慰剂组(6.4±0.5 vs 8.3±0.5 mm Hg,P=.011)。
- 血管加压素组术后48小时胸管引流量显著减少(23±20 vs 40±20 mL/kg,P=.028)。
核心结论
- Fontan术后血管加压素输注安全,并与早期跨肺压差和胸管引流量降低相关。
- 需要更大规模多中心研究进一步验证结局获益。
研究设计与样本
- 随机、双盲、安慰剂对照初步研究,纳入20例Fontan术后患者,血管加压素组与安慰剂组各10例。
- 干预为体外循环后持续24小时输注血管加压素,术后48小时内收集血流动力学、尿量、胸管引流、液体平衡及实验室数据,采用混合效应回归分析。
主要发现
- 血管加压素组跨肺压差显著低于安慰剂组(6.4±0.5 vs 8.3±0.5 mm Hg,P=.011)。
- 血管加压素组术后48小时胸管引流量显著少于安慰剂组(23±20 vs 40±20 mL/kg,P=.028)。
- 两组血钠浓度、肝功能和肾功能均无差异。
- 术后精氨酸加压素浓度在两组均高于基线直至心脏重症监护室入室后4小时,输注期间血管加压素组更高。
临床怎么用
- Fontan术后早期可考虑使用血管加压素以降低跨肺压差和胸管引流量,但需注意该研究为初步探索。
局限性
- 样本量小(仅20例),为单中心初步研究。
- 随访仅限术后48小时,未评估长期结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Arginine vasopressin is a nonapeptide hormone with effects on intracellular water transport and arterial tone that is used in distributive shock and following cardiopulmonary bypass. We sought to evaluate the safety and efficacy of vasopressin infusion on hemodynamics and fluid balance in the early postoperative period after Fontan completion. METHODS: We conducted a randomized, double-blinded, placebo-controlled study of vasopressin infusion for 24 hours after cardiopulmonary bypass for Fontan completion. Patient characteristics, hospital outcomes, and measures of hemodynamic parameters, urine output, chest tube drainage, fluid balance, laboratory data, and plasma arginine vasopressin concentrations were collected at baseline and for 48 postoperative hours. Data were analyzed using mixed-effect regressions. RESULTS: Twenty patients were randomized, 10 to vasopressin and 10 to placebo. Transpulmonary gradient (6.4 ± 0.5 vs 8.3 ± 0.5 mm Hg, P = .011) and chest tube drainage (23 ± 20 vs 40 ± 20 mL/kg, P = .028) for 48 hours after surgery were significantly lower in the vasopressin arm compared to placebo. Arginine vasopressin concentrations were elevated above baseline after surgery until 4 hours post cardiac intensive care unit admission in both arms, and higher in the vasopressin arm during postoperative infusion. No differences in sodium concentration, liver function, or renal function were noted between groups. CONCLUSIONS: Vasopressin infusion after Fontan completion appears safe and was associated with reduced transpulmonary gradient and chest tube drainage in the early postoperative period. A larger multiinstitutional study may show further outcome benefit.
引用
- Bigelow AM, Ghanayem NS, Thompson NE, et al. Safety and Efficacy of Vasopressin After Fontan Completion: A Randomized Pilot Study. Ann Thorac Surg. 2019. PMID: 31400337. doi:10.1016/j.athoracsur.2019.06.053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。